Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation

Biophysical Reviews

Volumn 9, Issue 4, 2017, Pages 405-419

  Stewart, Katie L ^a   Radford, Sheena E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

A beta; Alzheimer s disease; Amyloid plaques; Protein aggregation

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APTAMER; CARBOHYDRATE; CHOLESTEROL; COPPER ION; GANGLIOSIDE; GLYCOSAMINOGLYCAN; IRON; METAL ION; NUCLEIC ACID; PROTEOGLYCAN; SERUM AMYLOID P; ZINC ION;

AGITATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; DISEASE COURSE; DISEASE SEVERITY; LIPID RAFT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ISOLATION; PROTEIN METABOLISM; PROTEIN PURITY; REVIEW;

EID: 85028656565     PISSN: 18672450     EISSN: 18672469     Source Type: Journal    
DOI: 10.1007/s12551-017-0271-9     Document Type: Review

References (182)

1. Abelein A, Graslund A, Danielsson J (2015) Zinc as chaperone-mimicking agent for retardation of amyloid beta peptide fibril formation. Proc Natl Acad Sci U S A 112:5407–5412
2. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D (2006) A phase II study targeting amyloid-beta with 3APS in mild to moderate Alzheimer's disease. Neurology 67:1757–1763
3. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383–421
4. Alexandrescu AT (2005) Amyloid accomplices and enforcers. Protein Sci 14:1–12
5. Alzheimer A (1911) Concerning unsual medical cases in old age. Z Gesamte Neurol Psychiatr 4:356–385
6. Ancsin JB, Kisilevsky R (1999) The heparin heparan sulfate binding site on apo serum amyloid A- implications for the therapeutic intervention of amyloidosis. J Biol Chem 274:7172–7181
7. Annamalai K, Guhrs KH, Koehler R, Schmidt M, Michel H, Loos C, Gaffney PM, Sigurdson CJ, Hegenbart U, Schonland S et al (2016) Polymorphism of amyloid fibrils in vivo. Angew Chem Int Ed 55:4822–4825
8. Arispe N, Pollard HB, Rojas E (1993) Giant multilevel cation channels formed by Alzheimer's disease amyloid beta protein in bilayer membranes. Proc Natl Acad Sci U S A 90:10573–10577
9. Assoc., A.s (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12:459–509
10. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer A-beta by cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273:12817–12826
11. Audas TE, Audas DE, Jacob MD, Ho JJD, Khacho M, Wang ML, Perera JK, Gardiner C, Bennett CA, Head T et al (2016) Adaptation to stressors by systemic protein amyloidogenesis. Dev Cell 39:155–168
12. Audas TE, Lee S (2016) Stressing out over long noncoding RNA. Biochim Biophys Acta 1859:184–191
13. Ayton S, Faux NG, Bush AI, Initia ADN (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 6:e6760
14. Belaidi AA, Bush AI (2016) Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem 139:179–197
15. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG (2004) Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24:4181–4186
16. Bergamaschini L, Rossi E, Vergani C, De Simoni MG (2009) Alzheimer's disease: another target for heparin therapy. Sci World J 9:891–908
17. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid beta protein assembly: A-beta40 and A-beta42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100:330–335
18. Bitter T, Muir H (1966) Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest 45:963–975
19. Bjork I, Lindahl U (1982) Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 48:161–182
20. Bonar L, Cohen AS, Skinner MM (1969) Characterization of amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 131:1373–1375
21. Borysik AJ, Morten IJ, Radford SE, Hewitt EW (2007) Specific glycosaminoglycans promote unseeded amyloid formation from beta(2)-microglobulin under physiological conditions. Kidney Int 72:174–181
22. Bourgault S, Solomon JP, Reixach N, Kelly JW (2011) Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 50:1001–1015
23. Bravo R, Arimon M, Valle-Delgado JJ, Garcia R, Durany N, Castel S, Cruz M, Ventura S, Fernandez-Busquets X (2008) Sulfated polysaccharides promote the assembly of A-beta(1-42) peptide into stable fibrils of reduced cytotoxicity. J Biol Chem 283:32471–32483
24. Buell AK, Hung P, Salvatella X, Welland ME, Dobson CM, Knowles TP (2013) Electrostatic effects in filamentous protein aggregation. Biophys J 104:1116–1126
25. Bunka DHJ, Mantle BJ, Morten IJ, Tennent GA, Radford SE, Stockley PG (2007) Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem 282:34500–34509
26. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar A-beta in amyloid plaques. Brain Res Mol Brain Res 110:119–125
27. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A-beta amyloid formation by zinc. Science 265:1464–1467
28. Butterfield SM, Lashuel HA (2010) Amyloidogenic protein membrane interactions: mechanistic insight from model systems. Angew Chem Int Ed 49:5628–5654
29. Caballero AB, Terol-Ordaz L, Espargaro A, Vazquez G, Nicolas E, Sabate R, Gamez P (2016) Histidine-rich oligopeptides to lessen copper-mediated amyloid-beta toxicity. Chemistry 22:7268–7280
30. Calamai M, Kumita JR, Mifsud J, Parrini C, Ramazzotti M, Ramponi G, Taddei N, Chiti F, Dobson CM (2006) Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry 45:12806–12815
31. Camero S, Ayuso JM, Barrantes A, Benitez MJ, Jimenez JS (2013) Specific binding of DNA to aggregated forms of Alzheimer's disease amyloid peptides. Int J Biol Macromol 55:201–206
32. Cardin AD, Weintraub HJR (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9:21–32
33. Carter DB (2005) The interaction of amyloid-beta with ApoE. Subcell Biochem 38:255–272
34. Casadesus G, Smith MA, Zhu XW, Aliev G, Cash AD, Honda K, Petersen RB, Perry G (2004) Alzheimer's disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 6:165–169
35. Castillo GM, Lukito W, Wight TN, Snow AD (1999) The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 72:1681–1687
36. Cenini G, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G, Memo M, Uberti D (2010) Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 38:1101–1106
37. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS et al (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665–676
38. Clements A, Allsop D, Walsh DM, Williams CH (1996) Aggregation and metal binding properties of mutant forms of the amyloid A-beta peptide of Alzheimer's disease. J Neurochem 66:740–747
39. Coker AR, Purvis A, Baker D, Pepys MB, Wood SP (2000) Molecular chaperone properties of serum amyloid P component. FEBS Lett 473:199–202
40. Colin J, Gregory-Pauron L, Lanhers MC, Claudepierre T, Corbier C, Yen FT, Malaplate-Armand C, Oster T (2016) Membrane raft domains and remodeling in aging brain. Biochimie 130:178–187
41. Cremers CM, Knoefler D, Gates S, Martin N, Dahl JU, Lempart J, Xie LH, Chapman MR, Galvan V, Southworth DR et al (2016) Polyphosphate: a conserved modifier of amyloidogenic processes. Mol Cell 63:768–780
42. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang XD, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of A-beta by zinc. J Biol Chem 275:19439–19442
43. Cui H, King AE, Jacobson GA, Small DH (2017) Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice. J Neurosci Res 95:992–999
44. Dewitt DA, Silver J, Canning DR, Perry G (1993) Chondroitin sulfate poteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 121:149–152
45. Di Scala C, Yahi N, Boutemeur S, Flores A, Rodriguez L, Chahinian H, Fantini J (2016) Common molecular mechanism of amyloid pore formation by Alzheimer's beta-amyloid peptide and alpha-synuclein. Sci Rep 6:e28781
46. Di Scala C, Yahi N, Lelievre C, Garmy N, Chahinian H, Fantini J (2013) Biochemical identification of a linear cholesterol binding domain within Alzheimer's beta-amyloid peptide. ACS Chem Neurosci 4:509–517
47. Diaz-Nido J, Wandosell F, Avila J (2002) Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23:1323–1332
48. Dinkel PD, Holden MR, Matin N, Margittai M (2015) RNA binds to tau fibrils and sustains template-assisted growth. Biochemistry 54:4731–4740
49. Eichner T, Radford SE (2011) A diversity of assembly mechanisms of a generic amyloid fold. Mol Cell 43:8–18
50. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822
51. Esko JD, Kimata K, Lindahl U (2009) Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of glycobiology. Cold Spring Harbor, New York
52. Faller P (2009) Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal ion transfer. Chembiochem 10:2837–2845
53. Faller P, Hureau C (2009) Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans:1080–1094
54. Fantini J, Yahi N, Garmy N (2013) Cholesterol accelerates the binding of Alzheimer's beta-amyloid peptide to ganglioside GM1 through a universal hydrogen bond-dependent sterol tuning of glycolipid conformation. Front Physiol 4:1–10
55. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. J Am Med Assoc 278:1349–1356
56. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H et al (2010) PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis 20:509–516
57. Fletcher TG, Keire DA (1997) The interaction of beta-amyloid protein fragment (12-28) with lipid environments. Protein Sci 6:666–675
58. Fraser PE, Darabie AA, McLaurin J (2001) Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides- implications for drug development. J Biol Chem 276:6412–6419
59. Geddes AJ, Parker KD, Atkins EDT, Beighton E (1968) Cross-beta conformation in proteins. J Mol Biol 32:343–358
60. Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VMY, Eberwine JH, Trojanowski JQ (1999) Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 45:174–181
61. Ginsberg SD, Crino PB, Lee VMY, Eberwine JH, Trojanowski JQ (1997) Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol 41:200–209
62. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383:550–553
63. Goloubinoff P (2014) Recent and future grand challenges in protein folding, misfolding, and degradation. Front Mol Biosci 1:1–3
64. Gorevic PD, Castano EM, Sarma R, Frangione B (1987) Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X-ray diffraction pattern. Biochem Biophys Res Commun 147:854–862
65. Gunderson WA, Hernandez-Guzman J, Karr JW, Sun L, Szalai VA, Warncke K (2012) Local structure and global patterning of Cu2+ binding in fibrillar amyloid-beta [Abeta(1-40)] protein. J Am Chem Soc 134:18330–18337
66. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid-beta peptide. Nat Rev Mol Cell Biol 8:101–112
67. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184–185
68. Hare DJ, Faux NG, Roberts BR, Volitakis I, Martins RN, Bush AI (2016) Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian imaging, biomarkers and lifestyle flagship study of Ageing. Metallomics 8:628–632
69. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer's disease. Nat Rev Neurosci 16:358–372
70. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97:2892–2897
71. Huang XD, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD et al (1999) The A-beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616
72. Huang WJ, Zhang X, Chen WW (2016) Role of oxidative stress in Alzheimer's disease. Biomed Rep 4:519–522
73. Huang YWA, Zhou B, Wernig M, Sudhof TC (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A-beta secretion. Cell 168:427–441
74. Ikeda K, Matsuzaki K (2008) Driving force of binding of amyloid-beta protein to lipid bilayers. Biochem Biophys Res Commun 370:525–529
75. Inoue S (2008) In situ A-beta pores in AD brain are cylindrical assembly of A-beta protofilaments. Amyloid 15:223–233
76. Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45:1628–1650
77. Jendresen CB, Cui H, Zhang X, Vlodavsky I, Nilsson LNG, Li JP (2015) Overexpression of heparanase lowers the amyloid burden in amyloid-beta precursor protein transgenic mice. J Biol Chem 290:5053–5064
78. Jha S, Patil SM, Gibson J, Nelson CE, Alder NN, Alexandrescu AT (2011) Mechanism of amylin fibrillization enhancement by heparin. J Biol Chem 286:22894–22904
79. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627–1631
80. 2+ binding site in amyloid-beta. Biochemistry 44:5478–5487
81. Karr JW, Kaupp LJ, Szalai VA (2004) Amyloid-beta binds Cu2+ in a mononuclear metal ion binding site. J Am Chem Soc 126:13534–13538
82. Karr JW, Szalai VA (2008) Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide. Biochemistry 47:5006–5016
83. Khachaturian ZS (1987) Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiol Aging 8:345–346
84. Khmeleva SA, Radko SP, Kozin SA, Kiseleva YY, Mezentsev YV, Mitkevich VA, Kurbatov LK, Ivanov AS, Makarov AA (2016) Zinc-mediated binding of nucleic acids to amyloid-beta aggregates: role of histidine residues. J Alzheimers Dis 54:809–819
85. Kim W, Hecht MH (2006) Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's A-beta42 peptide. Proc Natl Acad Sci U S A 103:15824–15829
86. Kim SI, Yi JS, Ko YG (2006) Amyloid-beta oligomerization is induced by brain lipid rafts. J Cell Biochem 99:878–889
87. Kisilevsky R, Snow A (1988) The potential significance of sulfated glycosaminoglycans as a common constituent of all amyloids. Med Hypotheses 26:231–236
88. Kisilevsky R, Szarek WA (2002) Novel glycosaminoglycan precursors as anti-amyloid agents, part II. J Mol Neurosci 19:45–50
89. Kisilevsky R, Szarek WA, Ancsin J, Bhat S, Li ZJ, Marone S (2003) Novel glycosaminoglycan precursors as anti-amyloid agents, part III. J Mol Neurosci 20:291–297
90. Kiskis J, Fink H, Nyberg L, Thyr J, Li JY, Enejder A (2015) Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. Sci Rep 5:e13489
91. Knowles TPJ, Vendruscolo M, Dobson CM (2014) The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15:496–496
92. Komarova NL, Thalhauser CJ (2011) High degree of heterogeneity in Alzheimer's disease progression patterns. PLoS Comput Biol 7:e1002251
93. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu XG et al (2013) Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. J Neurosci 33:8423–8441
94. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, Rees HD, Lah JJ, Levey AI, Peng J (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279:37061–37068
95. Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M (1999) Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem 274:30631–30635
96. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA, Crowther DC (2011) Iron promotes the toxicity of amyloid-beta peptide by impeding its ordered aggregation. J Biol Chem 286:4248–4256
97. Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu GJ (2016) Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer's disease. Sci Transl Med 8:e332ra344
98. Loef M, Walach H (2012) Copper and iron in Alzheimer's disease: a systematic review and its dietary implications. Br J Nutr 107:7–19
99. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154:1257–1268
100. Madine J, Clayton JC, Yates EA, Middleton DA (2009) Exploiting a C13-labelled heparin analogue for in situ solid-state NMR investigations of peptide-glycan interactions within amyloid fibrils. Org Biomol Chem 7:2414–2420
101. Madine J, Pandya MJ, Hicks MR, Rodger A, Yates EA, Radford SE, Middleton DA (2012) Site-specific identification of an a fibril-heparin interaction site by using solid-state NMR spectroscopy. Angew Chem Int Ed 51:13140–13143
102. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer's disease. Nat Rev Dis Primers 1:15056–15074
103. Matsuzaki K (2007) Physicochernical interactions of amyloid peptide with lipid bilayers. Biochim Biophys Acta-Biomembr 1768:1935–1942
104. Matsuzaki K, Kato K, Yanagisawa K (2010) A-beta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta-Mol Cell Biol 1801:868–877
105. Mayes J, Tinker-Mill C, Kolosov O, Zhang H, Tabner BJ, Allsop D (2014) Beta-amyloid fibrils in Alzheimer's disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species. J Biol Chem 289:12052–12062
106. Mayeux R, Reitz C, Brickman AM, Haan MN, Manly JJ, Glymour MM, Weiss CC, Yaffe K, Middleton L, Hendrie HC et al (2011) Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment, part 1. Alzheimers Dement 7:15–34
107. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX (2005) Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 86:147–159
108. McLaurin J, Franklin T, Kuhns WJ, Fraser PE (1999a) A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity. Amyloid 6:233–243
109. McLaurin J, Franklin T, Zhang XQ, Deng JP, Fraser PE (1999b) Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans - effects on fibril nucleation and growth. Eur J Biochem 266:1101–1110
110. McLaurin J, Fraser PE (2000) Effect of amino acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. Eur J Biochem 267:6353–6361
111. Meisl G, Yang XT, Hellstrand E, Frohm B, Kirkegaard JB, Cohen SIA, Dobson CM, Linse S, Knowles TPJ (2014) Differences in nucleation behavior underlie the contrasting aggregation kinetics of the A-beta40 and A-beta42 peptides. Proc Natl Acad Sci U S A 111:9384–9389
112. Meneghetti MC, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA, Lima MA (2015) Heparan sulfate and heparin interactions with proteins. J R Soc Interface 12:e20150589
113. Meng FL, Raleigh DP (2011) Inhibition of glycosaminoglycan-mediated amyloid formation by islet amyloid polypeptide and proIAPP processing intermediates. J Mol Biol 406:491–502
114. Mold M, Ouro-Gnao L, Wieckowski BM, Exley C (2013) Copper prevents amyloid-beta(1-42) from forming amyloid fibrils under near-physiological conditions in vitro. Sci Rep 3:e1256
115. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, Scherr PA (2006) Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 63:1085–1088
116. Motamedi-Shad N, Monsellier E, Chiti F (2009a) Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism. J Biochem 146:805–814
117. Motamedi-Shad N, Monsellier E, Torrassa S, Relini A, Chiti F (2009b) Kinetic analysis of amyloid formation in the presence of heparan sulfate. J Biol Chem 284:29921–29934
118. Nandi PK, Leclerc E, Nicole JC, Takahashi M (2002) DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol 322:153–161
119. Okada T, Ikeda K, Wakabayashi M, Ogawa M, Matsuzaki K (2008) Formation of toxic A-beta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in A-beta(1-40) fibrils. J Mol Biol 382:1066–1074
120. Oohira A, Matsui F, Tokita Y, Yamauchi S, Aono S (2000) Molecular interactions of neural chondroitin sulfate proteoglycans in the brain development. Arch Biochem Biophys 374:24–34
121. Ozawa D, Nomura R, Mangione PP, Hasegawa K, Okoshi T, Porcari R, Bellotti V, Naiki H (2016) Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. Sci Rep 6:e29077
122. Paravastu AK, Leapman RD, Yau WM, Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A 105:18349–18354
123. Pedersen JT, Borg CB, Michaels TC, Knowles TP, Faller P, Teilum K, Hemmingsen L (2015) Aggregation-prone amyloid-beta Cu(II) species formed on the millisecond timescale under mildly acidic conditions. Chembiochem 16:1293–1297
124. Pedersen JT, Chen SW, Borg CB, Ness S, Bahl JM, Heegaard NH, Dobson CM, Hemmingsen L, Cremades N, Teilum K (2016) Amyloid-beta and alpha-synuclein decrease the level of metal-catalyzed reactive oxygen species by radical scavenging and redox silencing. J Am Chem Soc 138:3966–3969
125. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J et al (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A 91:5602–5606
126. Perreau VM, Orchard S, Adlard PA, Bellingham SA, Cappai R, Ciccotosto GD, Cowie TF, Crouch PJ, Duce JA, Evin G et al (2010) A domain level interaction network of amyloid precursor protein and A-beta of Alzheimer's disease. Proteomics 10:2377–2395
127. Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS et al (2002) Reactive oxygen: its sources and significance in Alzheimer's disease. Ageing Dement 62:69–75
128. Preston GW, Radford SE, Ashcroft AE, Wilson AJ (2012) Covalent cross-linking within supramolecular peptide structures. Anal Chem 84:6790–6797
129. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M (2002) Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 3:717–725
130. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6:345–351
131. Rahimi F, Murakami K, Summers JL, Chen CHB, Bitan G (2009) RNA aptamers generated against oligomeric A-beta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS ONE 4:e7694
132. Rao JN, Jao CC, Hegde BG, Langen R, Ulmer TS (2010) A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. J Am Chem Soc 132:8657–8668
133. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG (2001) Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord 12:408–414
134. Rezaei-Ghaleh N, Giller K, Becker S, Zweckstetter M (2011) Effect of zinc binding on beta-amyloid structure and dynamics: implications for A-beta aggregation. Biophys J 101:1202–1211
135. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, James W, Tahiri-Alaoui A (2003) Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 278:39697–39705
136. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A-beta amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691
137. Robertson DL, Joyce GF (1990) Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344:467–468
138. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer's disease brain tissue. J Neurochem 61:1916–1926
139. Rudd TR, Skidmore MA, Guimond SE, Guerrini M, Cosentino C, Edge R, Brown A, Clarke DT, Torri G, Turnbull JE et al (2008) Site-specific interactions of copper(II) ions with heparin revealed with complementary (SRCD, NMR, FTIR and EPR) spectroscopic techniques. Carbohydr Res 343:2184–2193
140. Sarell CJ, Karamanos TK, White SJ, Bunka DHJ, Kalverda AP, Thompson GS, Barker AM, Stockley PG, Radford SE (2014) Distinguishing closely related amyloid precursors using an RNA aptamer. J Biol Chem 289:26859–26871
141. Sarell CJ, Wilkinson SR, Viles JH (2010) Substoichiometric levels of Cu2+ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid-{beta} from Alzheimer disease. J Biol Chem 285:41533–41540
142. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789–791
143. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8:595–608
144. Serra-Batiste M, Ninot-Pedrosa M, Bayoumi M, Gairi M, Maglia G, Carulla N (2016) A-beta42 assembles into specific beta-barrel pore-forming oligomers in membrane-mimicking environments. Proc Natl Acad Sci U S A 113:10866–10871
145. Shafrir Y, Durell S, Arispe N, Guy HR (2010) Models of membrane-bound Alzheimer's A-beta peptide assemblies. Proteins 78:3473–3487
146. Shao HY, Jao SC, Ma K, Zagorski MG (1999) Solution structures of micelle-bound amyloid-beta(1-40) and -beta(1-42) peptides of Alzheimer's disease. J Mol Biol 285:755–773
147. Shearer J, Szalai VA (2008) The amyloid-beta peptide of Alzheimer's disease binds Cu(I) in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J Am Chem Soc 130:17826–17835
148. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease I. Review of epidemiological and preclinical studies. Arch Neurol 68:1239–1244
149. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569–572
150. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM, Westermark P (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 nomenclature guidelines. Amyloid 23:209–213
151. Sipe JD, Cohen AS (2000) Review: history of the amyloid fibril. J Struct Biol 130:88–98
152. Snow AD, Mar H, Nochlin D, Kresse H, Wight TN (1992) Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J Histochem Cytochem 40:105–113
153. Snow AD, Willmer J, Kisilevsky R (1987) Sulfated glycosaminoglycans- a common constituent of all amyloids. Lab Investig 56:120–123
154. So M, Hata Y, Naiki H, Goto Y (2017) Heparin-induced amyloid fibrillation of beta2-microglobulin explained by solubility and a supersaturation-dependent conformational phase diagram. Protein Sci 26:1024–1036
155. Sobel M, Soler DF, Kermode JC, Harris RB (1992) Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 267:8857–8862
156. Solomon JP, Bourgault S, Powers ET, Kelly JW (2011) Heparin binds 8 kDa gelsolin cross-beta-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry 50:2486–2498
157. Steenland K, Zhao LP, Goldstein FC, Levey AI (2013) Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc 61:1449–1455
158. Stewart KL, Hughes E, Yates EA, Akien GR, Huang TY, Lima MA, Rudd TR, Guerrini M, Hung SC, Radford SE et al (2016) Atomic details of the interactions of glycosaminoglycans with amyloid-beta fibrils. J Am Chem Soc 138:8328–8331
159. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericakvance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid-beta peptide - isoform-specific effects and implications for late onset Alzheimer’s disease. Proc Natl Acad Sci U S A 90:8098–8102
160. Szumanska G, Vorbrodt AW, Mandybur TI, Wisniewski HM (1987) Lectin histochemistry of plaques and tangles in Alzheimer’s disease. Acta Neuropathol 73:1–11
161. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299–4303
162. Thalhauser CJ, Komarova NL (2012) Alzheimer's disease: rapid and slow progression. J R Soc Interface 9:119–126
163. Tougu V, Tiiman A, Palumaa P (2011) Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. Metallomics 3:250–261
164. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment - RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510
165. Tycko R (2015) Amyloid polymorphism: structural basis and neurobiological relevance. Neuron 86:632–645
166. Ullrich C, Pirchl M, Humpel C (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45:408–417
167. Valle-Delgado JJ, Alfonso-Prieto M, de Groot NS, Ventura S, Samitier J, Rovira C, Fernandez-Busquets X (2010) Modulation of A-beta(42) fibrillogenesis by glycosaminoglycan structure. FASEB J 24:4250–4261
168. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders. Lancet Neurol 2:482–492
169. Varki A, Sharon N (2009) Historical background and overview. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of glycobiology. Cold Spring Harbor, New York
170. Verghese PB, Castellano JM, Garai K, Wang YN, Jiang H, Shah A, Bu GJ, Frieden C, Holtzman DM (2013) ApoE influences amyloid-beta clearance despite minimal apoE/A beta association in physiological conditions. Proc Natl Acad Sci U S A 110:E1807–E1816
171. Vieira TCRG, Cordeiro Y, Caughey B, Silva JL (2014) Heparin binding confers prion stability and impairs its aggregation. FASEB J 28:2667–2676
172. Virchow RLK, Chance F (1860) Cellular pathology as based upon physiological and pathological histology. Twenty lectures delivered in the pathological Institute of Berlin during the months of February, March, and April, 1858. Churchill, London
173. Wakabayashi M, Matsuzaki K (2009) Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts. FEBS Lett 583:2854–2858
174. Wang P, Wang ZY (2016) Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease. Ageing Res Rev 35:265–290
175. Warner RG, Hundt C, Weiss S, Turnbull JE (2002) Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 277:18421–18430
176. Williams EC, Huppert BJ, Asakura S (1992) Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid-P component - comparison with other plasma and platelet proteins. J Lab Clin Med 120:159–167
177. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, Frolich L, Schroder J, Peters O, Jessen F et al (2007) Amyloid beta peptide ratio 42/40 but not A-beta 42 correlates with phospho-Tau in patients with low- and high-CSF A-beta40 load. J Neurochem 101:1053–1059
178. Wong PT, Schauerte JA, Wisser KC, Ding H, Lee EL, Steel DG, Gafni A (2009) Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J Mol Biol 386:81–96
179. Woods AG, Cribbs DH, Whittemore ER, Cotman CW (1995) Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 697:53–62
180. Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE (2000) Examining the zinc binding site of the amyloid-beta peptide. Eur J Biochem 267:6692–6698
181. Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC (2017) Association of docosahexaenoic acid supplementation with Alzheimer's disease stage in apolipoprotein E epsilon4 carriers: a review. J Am Med Assoc Neurol 74:339–347
182. Ylera F, Lurz R, Erdmann VA, Furste JP (2002) Selection of RNA aptamers to the Alzheimer’s disease amyloid peptide. Biochem Bioph Res Commun 290:1583–1588